溴隐亭与帕金森病：16小时临床评估

Bromocriptine and Parkinson's disease: a 16-hour clinical evaluation.

作者信息

Grøn U, Friis M L, Pakkenberg H

出版信息

Acta Neurol Scand. 1980 Feb;61(2):131-6. doi: 10.1111/j.1600-0404.1980.tb01475.x.

DOI:10.1111/j.1600-0404.1980.tb01475.x

Abstract

The disability score (Webster rating scale) in 12 parkinsonian patients on bromocriptine treatment was evaluated hourly from 06-22 h. Bromocriptine was taken at fixed hours (06, 14, and 22 h) in equal doses. No systematic changes during the day related to bromocriptine ingestion were observed. Only one patient experienced pronounced hyperkinesia, "On-off" phenomenas were not observed during the treatment with bromocriptine.

摘要

对12例接受溴隐亭治疗的帕金森病患者，在06:00至22:00期间每小时评估一次残疾评分（韦伯斯特评定量表）。溴隐亭在固定时间（06:00、14:00和22:00）等量服用。未观察到与服用溴隐亭相关的白天系统性变化。仅1例患者出现明显的运动障碍，在溴隐亭治疗期间未观察到“开-关”现象。